ArticleJournal of healthcare engineering2022
Role of MiR-27a-3p in Intervertebral Disc Degeneration through Targeting RASSF5 via MST1/LATS1 and RAS/RAC1 Signaling Pathway.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- microRNA profilings identify plasma biomarkers and targets associated with pediatric epilepsy patients.Pediatric research · 2024Article
- Article
- Degenerated nucleus pulposus cells derived exosome carrying miR-27a-3p aggravates intervertebral disc degeneration by inducing M1 polarization of macrophages.Journal of nanobiotechnology · 2023Article
- Retracted: Role of MiR-27a-3p in Intervertebral Disc Degeneration through Targeting RASSF5 via MST1/LATS1 and RAS/RAC1 Signaling Pathway.Journal of healthcare engineering · 2023Article
Corrections and comments
- Retraction · 2023-08-16Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Informed/Patient Consent - None/Withdrawn · Investigation by Journal/Publisher · Investigation by Third Party · Lack of IRB/IACUC Approval and/or Compliance · Paper Mill · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The apoptosis of nucleus pulposus (NP) cells reduces the number of nucleus pulposus cells in intervertebral disc tissue, resulting in intervertebral disc degeneration (IDD). MicroRNAs (miRNAs) play an important regulatory role in abnormal cell proliferation and apoptosis. Methods: The miR-27a-3p expressions in degenerative NP tissue and cells were measured via qPCR. The impacts of miR-27a-3p on the proliferation and apoptosis of human NP cells were evaluated by flow cytometry assays, MTT assays, and western blot analyses. In addition, target scan and luciferase reporter assay were applied to confirm that RASSF5 was directly binding to miR-27a-3p. Western blot was applied to assess the relationship between miR-27a-3p, RASSF5 and MST1/LATS1, and RAS/RAC1 signaling pathway. Results: MiR-27a-3p was downregulated in degenerative NP tissues and cells by comparison with the control group. MiR-27a-3p overexpression enhanced cell proliferation and suppressed apoptosis of NP cells, while the above factors showed an opposite tendency after in the miR-27a-3p inhibitor group. The western blot experiment similarly suggested mir-27a-3p apparently downregulated apoptosis-related proteins (Bax and caspase-3) and upregulated antiapoptotic proteins (Bcl-2). In addition, RASSF5 was confirmed to be directly regulated by miR-27a-3p using the luciferase reporter assay. Overexpressed RASSF5 could reverse the effects caused by miR-27a-3p mimic. Finally, miR-27a-3p could downregulate RASSF5 and affected the MST1/LATS1 and RAS/RAC1 pathway. Conclusion: MiR-27a-3p may target RASSF5 and enhance cell proliferation and imped cell apoptosis of the nucleus pulposus cells via the MST1/LATS1 and RAS/RAC1 pathway, lessening the degeneration of intervertebral discs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.